Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
Biohaven Ltd. (BHVN) Stock Price & Analysis
326 Followers
BHVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.45 - $62.21
Previous Close$41.21
Volume1.23M
Average Volume (3M)1.23M
Market Cap
$3.64B
Enterprise Value$3.28B
Total Cash (Recent Filing)$381.82M
Total Debt (Recent Filing)$27.57M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Nov 06, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.84
Shares Outstanding88,291,909
10 Day Avg. Volume1,092,771
30 Day Avg. Volume1,234,235
Standard Deviation0.41
R-Squared0.20
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)7.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-19.07
Forecast
1Y Price Target
$58.63Price Target Upside47.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Biohaven Ltd. News
PremiumThe Fly
Biohaven falls -18.4%
PremiumThe Fly
Biohaven falls -27.3%
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBHV-7000 (Kv7 activator) Phase 2/3 trials are underway in epilepsy, major depressive disorder, and bipolar disorder, showing promise in central nervous system conditions.
Pipeline DiversityBiohaven Limited is recognized as a unique smid-cap biotech company with a diverse pipeline offering upside optionality.
Safety ProfileBHV-1300 continues to demonstrate a favorable tolerability and safety profile, with most adverse events considered mild and resolving spontaneously.
Bears Say
Data DisclosureAbsence of hard data in last month's update led to a sharp selloff and reduced enthusiasm.
EarningsBiohaven posted a non-GAAP loss per share of $1.77, above the estimate of $1.37 loss per share.
Financial PerformanceNon-GAAP R&D expenses surged 120.0% YoY to $134.7M from $61.2M in 1Q23.
---
Ownership Overview
15.70% Insiders
25.24% Mutual Funds
16.81% Other Institutional Investors
42.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $16.45 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Currently, no data Available
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Nov 06, 2024 which is in 99 days.
How were Biohaven Ltd.’s earnings last quarter?
Currently, no data Available
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 88,291,910 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biohaven Ltd.?
Among the largest hedge funds holding Biohaven Ltd.’s share is Perceptive Advisors LLC. It holds Biohaven Ltd.’s shares valued at 94M.
---
Biohaven Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.63 (47.61% Upside)
$58.63 (47.61% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 524.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
108.50%
12-Months-Change
Fundamentals
Return on Equity
-133.69%
Trailing 12-Months
Asset Growth
-32.33%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Month Forecast
Average Price Target
$58.63
▲(47.61% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+91.59%
reiterated a buy rating 2 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +91.59% per trade.
---